Food and drug administration Approves New Management of Brittle bones In Postmenopausal Women At High-risk For Fracture

 

Continuing Treatment in Postmenopausal Women with Osteoporosis

Video taken from the channel: HCPLive


 

Investigational Drug Abaloparatide-sc Can Help Postmenopausal Women with Osteoporosis

Video taken from the channel: HCPLive


 

FDA Approval On Osteoporosis

Video taken from the channel: FOX 4 Now


 

TYMLOS for Postmenopausal Women with Osteoporosis

Video taken from the channel: Health Professional Radio


 

What to know about postmenopausal osteoporosis

Video taken from the channel: KC Spotlight


 

Tymlos Provides an Alternative Treatment for Women with Postmenopausal Menopause

Video taken from the channel: HCPLive


 

Osteoporosis: A Balanced Perspective on How to Minimize the Risk of Fracture as We Age

Video taken from the channel: University of California Television (UCTV)


The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women. Evenity (romosozumab) is a type of therapy known as a monoclonal antibody, and it helps build new bone by blocking the effect of a protein called sclerostin, the agency explained. Evenity’s.

“Today’s approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk,” Dr. Hylton V. Joffe, director of the FDA. The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women.

SILVER SPRING, Md. /PRNewswire/ The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

Officials with the FDA have approved romosozumab-aqqg (Evenity, Amgen) for the treatment of osteoporosis in postmenopausal women at high risk of fracture, according to a press release. TUESDAY, April 9, 2019 Evenity (romosozumab-aqqg) was approved for the treatment of osteoporosis in postmenopausal women with a high risk for fracture, the U.S. Food and Drug Administration announced. Evenity, a monoclonal antibody, blocks the effects.

THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect.

Evenity (romosozumab) is indicated for the treatment of osteoporosis in post-menopausal women at high risk of breaking a bone. It’s intended for women with a history of osteoporotic fracture. TYMLOS (abaloparatide) was approved by the U.S.

Food and Drug Administration or the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

List of related literature:

Tamoxifen shows agonistic estrogenic activity in bone and reduces risk of fracture in postmenopausal but not in premenopausal women.

“Encyclopedia of Cancer” by Manfred Schwab
from Encyclopedia of Cancer
by Manfred Schwab
Springer Berlin Heidelberg, 2011

Nevertheless, the U.S. Food and Drug Administration (FDA) has removed estrogen from the list of agents approved as effective in treating women who already have osteoporosis.

“Textbook of Natural Medicine E-Book” by Joseph E. Pizzorno, Michael T. Murray
from Textbook of Natural Medicine E-Book
by Joseph E. Pizzorno, Michael T. Murray
Elsevier Health Sciences, 2012

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.

“Integrative Medicine E-Book” by David Rakel
from Integrative Medicine E-Book
by David Rakel
Elsevier Health Sciences, 2012

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treatment with raloxifene: results from a 3-year randomized clinical trial.

“Primary Care Medicine: Office Evaluation and Management of the Adult Patient” by Allan H. Goroll, Albert G. Mulley
from Primary Care Medicine: Office Evaluation and Management of the Adult Patient
by Allan H. Goroll, Albert G. Mulley
Wolters Kluwer Health/Lippincott Williams & Wilkins, 2009

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial.

“Principles of Bone Biology” by John P. Bilezikian, Lawrence G. Raisz, T. John Martin
from Principles of Bone Biology
by John P. Bilezikian, Lawrence G. Raisz, T. John Martin
Elsevier Science, 2008

Physicians should recommend bone mineral density testing to younger women at risk and postmenopausal women younger than 65 years who have risk factors for osteoporosis other than being postmenopausal.

“Bratton's Family Medicine Board Review” by Robert L. Bratton
from Bratton’s Family Medicine Board Review
by Robert L. Bratton
Wolters Kluwer Health, 2012

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013.

“Williams Textbook of Endocrinology” by Shlomo Melmed, MBChB, MACP, Kenneth S. Polonsky, MD, P. Reed Larsen, MD, FRCP, Henry M. Kronenberg, MD
from Williams Textbook of Endocrinology
by Shlomo Melmed, MBChB, MACP, Kenneth S. Polonsky, MD, et. al.
Elsevier Health Sciences, 2015

Indeed, further investigation is required because studies in primary osteoporosis in postmenopausal women have not conclusively demonstrated fracture benefit.

“Principles of Gender-specific Medicine” by Marianne J. Legato, John P. Bilezikian
from Principles of Gender-specific Medicine
by Marianne J. Legato, John P. Bilezikian
Elsevier Academic Press, 2004

The change proposed would result in replacing the indications “prevention and treatment of osteoporosis” with the statement that the agent is approved for “treatment of osteoporosis in women at increased risk for fracture.”

“Osteoporosis” by Robert Marcus, David Feldman, Dorothy Nelson, Clifford Rosen
from Osteoporosis
by Robert Marcus, David Feldman, et. al.
Elsevier Science, 2007

• Postmenopausal women younger than 65 years who have an independent clinical risk factor for fracture (see below) and at least one additional indicator of low BMD and who are confirmed to have osteoporosis.

“Orthopaedic and Trauma Nursing: An Evidence-based Approach to Musculoskeletal Care” by Sonya Clarke, Julie Santy-Tomlinson
from Orthopaedic and Trauma Nursing: An Evidence-based Approach to Musculoskeletal Care
by Sonya Clarke, Julie Santy-Tomlinson
Wiley, 2014

Oktay Kutluk

Kutluk Oktay, MD, FACOG is one of the world's foremost experts in fertility preservation as well as ovarian stimulation and in vitro fertilization for infertility treatments. He developed and performed the world's first ovarian transplantation procedures as well as pioneered new ovarian stimulation protocols for embryo and oocyte freezing for breast and endometrial cancer patients.

Mail: [email protected]
Telephone: +1 (877) 492-3666

Biography: https://medicine.yale.edu/profile/kutluk_oktay/
Bibliography: oktay_bibliography

View all posts

2 comments

Your email address will not be published. Required fields are marked *

  • the FDA rigorous, you said? What about VIOXX? and so many drugs allowed to the market, then withdrawn quickly after harming-or even killing-thousands of people?

  • Wonder what forms of calcium the study used that decreased cardio, kidney health. What are the co nutrients of calcium. Bones are calcium, phosphorus,magnesium and other trace minerals. Also collagen. Have read vite D can pull calcium from bones if not taking enough calcium or can deposit it in arteries, is that true. Read that vite K2 (tempe, grass fed liver, cheese…) can help put the calcium into the helpful places. Also each person needs a little bit different things. How often does our body break down bone and rebuild? WOuld a pattern of take a drug off / on. Also some foods are high oxalic acid if effect loosing bone density, espec wonder about the fluoride thats put in our water as read it can effect bone/teeth health.